Takepron OD Indications/Uses

Short-Term Treatment of Active Duodenal Ulcer: TAKEPRON is indicated for short-term treatment (for four weeks) for healing and symptom relief of active duodenal ulcer (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence: Triple Therapy: TAKEPRON/amoxicillin/clarithromycin: TAKEPRON in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Please refer to the full prescribing information for amoxicillin and clarithromycin.
Dual Therapy: TAKEPRON/amoxicillin: TAKEPRON in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin prescribing information, Microbiology section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Please refer to the full prescribing information for amoxicillin.
Maintenance of Healed Duodenal Ulcers: TAKEPRON is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Short-Term Treatment of Active Benign Gastric Ulcer: TAKEPRON is indicated for short-term treatment (up to eight weeks) for healing and symptom relief of active benign gastric ulcer (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Healing of NSAID-Associated Gastric Ulcer: TAKEPRON is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond eight weeks (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Risk Reduction of NSAID-Associated Gastric Ulcer: TAKEPRON is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Gastroesophageal Reflux Disease (GERD): Short-Term Treatment of Symptomatic GERD: TAKEPRON is indicated for the treatment of heartburn and other symptoms associated with GERD for up to eight weeks (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Short-Term Treatment of Erosive Esophagitis: TAKEPRON is indicated for short-term treatment (up to eight weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with TAKEPRON for eight weeks (5 to 10%), it may be helpful to give an additional eight weeks of treatment. If there is a recurrence of erosive esophagitis an additional eight-week course of TAKEPRON may be considered (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Maintenance of Healing of Erosive Esophagitis (EE): TAKEPRON is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).
Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome (ZES): TAKEPRON is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome (see Pharmacology: Pharmacodynamics: Clinical Studies under Actions).